<DOC>
	<DOCNO>NCT00927810</DOCNO>
	<brief_summary>This 24-week open-label extension study design provide additional long-term safety data total 1-year patient roll core study , collect efficacy tolerability data patient , irrespective whether acute flare gout . Patients treated demand canakinumab ( ACZ885 ) extension study .</brief_summary>
	<brief_title>Long Term Study Canakinumab ( ACZ885 ) Patients With Gout</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients complete core study CACZ885H2251 . A patient define complete core study he/she complete study include last visit ( Visit 9 ) . Patients sign write informed consent trial procedure perform . Patients continuation extension 1 consider appropriate treat physician . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive pregnancy test ( serum urine ) . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Gout</keyword>
	<keyword>Gouty arthritis</keyword>
	<keyword>Gout flare</keyword>
	<keyword>Anti-interleukin-1Î² monoclonal antibody</keyword>
</DOC>